Announced Date: 2024-01-09 (January 09, 2024) Buyer: GSK plc (GSK) Seller: Aiolos Bio, Inc. (Aiolos) Key … [China Original Asset] GSK and Aiolos Bio enters a 1.4 billion USD Acquisition for TSLP Abs AIO-001 (SHR-1905 from Hengrui)Read more
[China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)
Announced Date: 2024-01-04 (January 4, 2024) Asset Name: AVZO-021 (ARTS-021) Licensor (Seller): Allorion Therapeutics (China) Licensee … [China BD 2024] Allorion and Avenzo enters a 1 billion USD License on CDK2 Inhibitor AVZO-021 (ARTS-021)Read more
[China BD 2024] Argo and Novartis enters a 4 billion USD license on two RNAi programs
Announced Date: 2024-01-07 (January 7, 2024) Asset Name: Two RNAi programs (RNA interference) Licensor: Argo (Shanghai … [China BD 2024] Argo and Novartis enters a 4 billion USD license on two RNAi programsRead more
[China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a preclinical KAT6 inhibitor ISM5043 (MEN2312)
Announced Date: 2024-01-04 (January 4, 2024) Asset Name: ISM5043 (MEN2312) Licensor: InSilico Medicine (China) Licensee (Buyer): … [China BD 2024] Insilico Medicine and Menarini (Stemline) enters a 512 million USD license on a preclinical KAT6 inhibitor ISM5043 (MEN2312) Read more
[China BD 2024] MediLink and Roche enters a 1 billion USD license on c-Met ADC YL211 (RG6648)
Announced Date: 2024-01-02 (January 2, 2024) Asset Name: YL211 (RG6648) Licensor: MediLink (MediLink Therapeutics, China) Licensee … [China BD 2024] MediLink and Roche enters a 1 billion USD license on c-Met ADC YL211 (RG6648)Read more
[China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor Asset
Announced Date: 2024-01-02 (January 2, 2024) Asset Name: Undisclosed Licensor (Seller): Allorion Therapeutics (China) Licensee (Buyer): AstraZeneca … [China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor AssetRead more
[China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093
Announced Date: 2023-12-20 (December 20, 2023) Asset Name: HS-20093 Licensor: Hansoh Pharma (Hansoh) (China) Licensee (Buyer): … [China BD Deal 2023] Hansoh and GSK enters a 1.71 billion USD license on B7-H3 ADC HS-20093Read more
[China BD 2023] GenFleet and Verastem enters Collaboration, Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program
Initial Announced Date: 2023-08-28 (August 28, 2025), Updated in 2023-12-18 (December 18, 2023) Asset: Three oncology … [China BD 2023] GenFleet and Verastem enters Collaboration, Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead ProgramRead more
[China BD Deal 2023] SystImmune and BMS enters a 8.4 billion USD license on bispecific EGFRxHER3 ADC BL-B01D1
Announced Date: 2023-12-11 (December 11, 2023) Asset Name: BL-B01D1 Licensor: SystImmune Inc., (a member of Sichuan … [China BD Deal 2023] SystImmune and BMS enters a 8.4 billion USD license on bispecific EGFRxHER3 ADC BL-B01D1Read more
[China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858
Announced Date: 2023-11-20 (November 20, 2023) Asset Name: HSK31858 Licensor: Haisco Pharmaceutical Group (China) and Licensee … [China BD 2023] Haisco and Chiesi enters a 475 million USD license on DPP1 inhibitor HSK31858Read more